Navigation Links
American Oriental Bioengineering Inc. Announces Plans for Reverse Stock Split of its Common Stock
Date:2/21/2012

NEWARK, N.J., Feb. 21, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) (the "Company") today announced that on January 31, 2012, its board of directors adopted resolutions approving a reverse stock split (the "Reverse Split") of the outstanding shares of the Company's common stock ("Common Stock") at a ratio of one (1) share for every two (2) shares outstanding, so that every two (2) outstanding shares of Common Stock before the Reverse Split shall represent one (1) share of Common Stock after the Reverse Split.

Pursuant to the Company's Amended Articles of Incorporation filed with the Nevada Secretary of State, the maximum number of shares of Common Stock that the Company is authorized to issue will also be reduced from 150,000,000 to 75,000,000.  The Reverse Split will be effected without obtaining shareholder approval pursuant to Nevada law.  The effective date of the Reverse Split with the Nevada Secretary of State is set for Friday, February 24, 2012.  Accordingly, the New York Stock Exchange has set the effective date of the Reverse Split for Monday, February 27, 2012. The Reverse Split is part of the Company's strategy to maintain the listing of its shares on the New York Stock Exchange.

Currently, the Company has approximately 78,503,381 shares of Common Stock outstanding. After the Reverse Split, the Company would have approximately 39,251,867 shares outstanding.  Each stockholder's percentage ownership interest in the Company and proportional voting power will remain unchanged after the Reverse Split except for minor changes and adjustments resulting from rounding of fractional interests.  The rights and privileges of the holders of Common Stock shall be substantially unaffected by the Reverse Split.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.  Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements.  The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, may cause actual results or events to differ materially from those described in the forward looking statements in this press release.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:

Hong Zhu
646-367-1765


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Association for Homecare Calls for Market-Based Alternative to Medicares Bidding Program; Cites Lack of Access for Beneficiaries
2. American Academy of Dermatology and LEO Pharma Launch Educational Website to Raise Awareness About Sun Damage and Skin Cancer
3. MiMedx Announces Nationwide Launch of AmnioFix® Injectable at American Academy of Orthopaedic Surgeons Annual Meeting
4. American Pacific to Release Financial Results and Hold Fiscal 2012 First Quarter Investor Teleconference
5. Partnership Between Lilly Diabetes and the American Diabetes Association to Send 89 Children to American Diabetes Association Diabetes Camps in 2012
6. In Honor of American Heart Month, Joy Behar & Daughter Eve Call on Women to Take the ProHeart Pledge on Facebook
7. Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Arias Technology
8. NBA, American Diabetes Association and Sanofi US Tip Off 2012 Dribble to Stop Diabetes Campaign
9. Triple-S Salud and American Health Medicare Partner With MedAssurant
10. BHI Urges People with Heart Disease to Get Their Hearing Checked During American Heart Month
11. American Consumer Institute Warns FTC: ESI/Medco Deal Poses Significant Anticompetitive Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... BOTHELL, Wash. , May 4, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... media ("BioLife" or the "Company"), today announced that ... released after market close on Thursday, May 11, 2017, ... and live webcast at 1:30 p.m. PT that afternoon. ...
(Date:5/3/2017)... May 3, 2017  Kalorama Information notes that ... percent next year and this is projected to ... stem cell (HSCT) or bone marrow transplants require ... are well-suited for this task. This according to ... Kalorama Information. The various PCR-based methodologies, Sanger sequencing ...
(Date:5/3/2017)... May 3, 2017  West Pharmaceutical Services, Inc. ... for injectable drug administration, announced today that ... Technical Services, and Diane Paskiet , Director, ... presentations focused on West,s expertise in the areas ... well as providing commentary on updated industry guidance. ...
Breaking Medicine Technology:
(Date:5/19/2017)... City, Mo (PRWEB) , ... May 19, 2017 , ... ... Saturday, May 20, his name will already appear on two major research studies that ... has been working with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside ...
(Date:5/19/2017)... CA (PRWEB) , ... May 19, 2017 , ... The ... consulting to families and entrepreneurs throughout the California Central Valley, is announcing a joint ... of raising community support for a local kid’s camp event. , The Boys and ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... class of Beckman Young Investigators: , Victor Acosta, Ph.D. - University of New ... Dan Fu, Ph.D. - University of Washington, Erik Grumstrup, Ph.D. - Montana Stata ...
(Date:5/19/2017)... ... ... As a groundbreaking surgeon on the frontline of prostate cancer treatment, ... of the disease, he says, can make a world of difference. ... the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and its suggestion to ...
(Date:5/19/2017)... ... , ... CloSYS products which are marketed as the gentle giants of the ... gum health, which is linked to one’s overall health. Since 1991 when the CloSYS ... ways in which CloSYS products immediately helped eliminate bad breath as well as help ...
Breaking Medicine News(10 mins):